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SUMMARY STATEMENT 
The metabolic sensor protein kinase AMPK is a key regulator of acute retinal 




Many neuronal and retinal disorders are associated with pathological 
hyperpermeability of the microvasculature. We have used explants of rodent retinae 
to study acute neurovascular permeability and signal transduction and the role of 
AMP-activated protein kinase (AMPK). Following stimulation with either vascular 
endothelial growth factor (VEGF-A) or bradykinin (BK), AMPK was rapidly and 
strongly phosphorylated and acted as a key mediator of permeability downstream of 
Ca2+. Accordingly, AMPK agonists potently induced acute retinal vascular leakage. 
AMPK activation led to phosphorylation of endothelial nitric oxide synthase (eNOS), 
which in turn increased VE-cadherin phosphorylation on Y685. In parallel, AMPK 
also mediated phosphorylation of p38 MAP kinase and HSP27, indicating that it 
regulated paracellular junctions and cellular contractility, both previously associated 
with endothelial permeability. Endothelial AMPK provided a missing link in 
neurovascular permeability, connecting Ca2+ transients to the activation of eNOS 
and p38, irrespective of the permeability-inducing factor used. Collectively, we find 
that, due to its compatibility with small molecule antagonists/agonists and siRNA, the 
ex-vivo retina model constitutes a reliable tool to identify and study regulators and 


























Leakage within the vascular system can be the cause or a significant co-morbidity of 
a variety of pathologies and is the consequence of endothelial hyperpermeability, 
which leads to extravasation of fluids and proteins, resulting in interstitial oedema 
(Nagy et al., 2008, Claesson-Welsh et al., 2020). In the nervous system, where the 
vasculature is uniquely impermeable and is referred to as the blood-brain barrier 
(BBB), vascular leakage accompanies stroke, multiple sclerosis, Parkinsons Disease 
as well as various forms of dementia (Turowski, 2017, Sweeney et al., 2019). 
Neurovascular leakage also affects the blood-retinal barrier (BRB), where it is a 
hallmark feature of diabetic retinopathy and neovascular age-related macular 
degeneration (Klaassen et al., 2013). Leakage during retinopathies is driven by 
permeability-inducing factors (PIFs), most prominently by the angiogenic growth 
factor VEGF-A; and VEGF-A antagonists are successfully used to reduce oedema 
and abnormal vessel growth, and restore neuronal dysfunction (Brown et al., 2013). 
Meta-analysis of the clinical use of anti-VEGFs in diabetic macular oedema suggests 
that PIFs other than VEGF-A play an important role in the pathogenesis of retinal 
leakage disease (Ford et al., 2013), including angiopoeitin-2 (Campochiaro and 
Peters, 2016), lyso-phosphatidylcholine (Canning et al., 2016) and BK (Kita et al., 
2015).  
PIFs induce both acute and chronic vascular leakage. For instance, exposure of the 
vascular endothelium to VEGF-A leads to acute permeability that usually lasts less 
than 30 min. If not resolved persistent leakage ensues that chronically impairs 
vascular integrity (Nagy et al., 2008, Bates, 2010, Claesson-Welsh et al., 2020). 























all permeability responses involve paracellular junction modulation or formation of 
transport vesicles (Nagy et al., 2008, Turowski, 2017, Claesson-Welsh et al., 2020), 
suggesting that ECs regulate hyperpermeability through a core molecular machinery 
and common downstream signalling. Indeed, e.g. Ca2+ transients, phosphorylation of 
the MAP kinase p38 and enhanced actin contractility are associated with all vascular 
permeability, as is activation of eNOS (Wu et al., 1999, Hudson et al., 2014, Weidert 
et al., 2014, Di Lorenzo et al., 2013, Takeshi Ninchoji, 2020). Adherens and tight 
junction modulation is associated with paracellular permeability and the 
phosphorylation of VE-cadherin (VE-cad) is associated with acute permeability in the 
periphery and the retina (Orsenigo et al., 2012, Smith et al., 2020). In the retina the 
phosphorylation of occludin on S490 and its subsequent internalisation also plays an 
important role, at least in a more chronic setting (Murakami et al., 2012). Identifying 
core signalling, on which all leakage responses depend, is desirable for therapeutic 
development as it would allow treatment without prior knowledge of specific known 
(or unknown) extracellular PIF.  
In the brain and the retina, entirely different signalling is induced by VEGF-A in ECs 
when it is added luminally (from the blood side) or abluminally (from the tissue side), 
with leakage-inducing signalling entirely restricted to abluminal stimulation (Hudson 
et al., 2014). For instance, leakage-associated p38 activation is triggered by 
abluminal (basal) VEGF-A stimulation, whilst activation of the PI3K/AKT pathway, 
which does not mediate permeability, is only seen following luminal (apical) 
stimulation. Thus, signalling specific to leakage can be inferred by comparing cellular 
stimulation following luminal and abluminal addition of VEGF-A. Conversely, BK 
efficiently induces permeability from the basal as well as apical side of cerebral or 
























AMP-activated protein kinase (AMPK) is a phylogenetically conserved energy sensor 
that regulates energy homeostasis by coordinating metabolic pathways and thus 
balancing energy requirement with nutrient supply (Hardie, 2018). Previous studies 
suggest that AMPK acts as a protector of the BBB integrity, for instance by 
preventing LPS-enhanced NAD(P)H oxidase expression in ECs and the consequent 
barrier dysfunction and enhanced permeability (Zhao et al., 2014, Ange et al., 2020). 
Moreover, AMPK mediates up-regulation of BBB functions induced in vitro by 
metformin, a drug used for the treatment of diabetes (Takata et al., 2013). 
Nevertheless, in the retina AMPK activation can lead to the breakdown of the outer, 
non-vascular BRB, which is constituted by the retinal pigment epithelium (Villarroel et 
al., 2011). However, if and how AMPK contributes to permeability induction by 
agonists such as VEGF-A or BK in neural microvessels is unknown. 
To identify and validate core components mediating acute permeability in 
neurovascular ECs, we adopted an ex vivo retinal preparation, originally described 
for rats (Warboys et al., 2009). Development of this method allowed measurement of 
real time changes of permeability and signalling in intact BRB vessels from rat and 
mouse. Importantly, this model system was compatible with precise pharmacokinetic 
agonist studies, parallel IHC staining and manipulation using siRNA. Our workflow 
can be used to identify core regulators of CNS endothelial hyperpermeability and 
was validated by identifying AMPK as a novel, key regulator linking VEGF-A or BK-



























VEGF-A and BK-induced permeability and junctional changes in brain 
microvascular ECs. 
Treatment of primary rat brain microvascular ECs with VEGF-A or BK significantly 
reduced TEER, indicating that paracellular permeability was induced (Figure 1A and 
B). TEER dropped immediately and reached a minimum within less than 5 min after 
addition of either VEGF-A or BK before reverting to control levels within 1 h. 
Thereafter, another significant, but more modest reduction in TEER was observed, 
indicative of a more chronic change in cell monolayer permeability. In order to 
correlate TEER changes with paracellular junction breakdown, the distribution of 
occludin and VE-Cad was analysed in VEGF-A- and BK-stimulated primary brain 
microvascular ECs (Figure 1C). As judged by confocal microscopy, occludin 
expression and distribution remained unchanged for up to 2 h of VEGF-A or BK 
stimulation. VE-cad levels also remained unchanged, but a broadening of the 
staining was observed within 5 min of the addition of the PIF, in particular at and 
around tricellular junctions. In agreement, cryo-immuno–EM of hCMEC/D3 cells 
revealed a significant relocation of VE-cad from the junctions to the cell interior by an 
average distance of 55 and 66 nm following a 5-min stimulation with VEGF-A and 
BK, respectively (Figure 1D-G). These results showed that single addition of either 
VEGF-A or BK induced acute and chronic permeability, and that the acute response 

























Validation of a modified ex-vivo retinal model 
In order to study the acute phase of VEGF-A- and BK-induced permeability in intact 
retinal microvessels in real time, we adopted an ex-vivo retinal model (Warboys et 
al., 2009). Permeability measurements used rat retinal explants, in which the 
vasculature was stabilised with a cardioplegic solution. To assess if the ex vivo 
preparation and perfusions led to alterations of the retinal vasculature and to 
determine stability of the preparation, we compared directly perfused fixed retinae 
with others, perfused with cardioplegic solution and left under superfusion with Krebs 
solution for 1 h before fixation. Subsequent whole mount staining for the tight 
junction protein claudin-5 and the   protein VE-cad revealed characteristic strands of 
continuous paracellular staining (Figure 2A, B) in both preparations. Importantly, the 
staining pattern was indistinguishable between the two different preparations, 
indicating that the perfusion did not cause significant disturbances of endothelial 
junctions. Permeability measurements were carried out by monitoring 
sulforhodamine B loss from individual microvessels (Supplemental Figure 1A, B). 
Baseline permeability to sulforhodamine-B was very low and on average 0.2 ± 0.16x 
10-6 cm/s. Taken together these data showed that morphological and barrier 
properties of the retinal microvasculature were well preserved in these preparations. 
Stimulation of the ex-vivo retina with VEGF-A or BK induced an immediate, marked 
loss of sulforhodamine B from the microvessel lumen, which was similar for both 
stimuli and amounted to a ca. 3-fold increase in microvessel permeability (Figures 
2C-F). Preincubation of the ex-vivo retina with VEGFR2 inhibitor SU-1498 for 15 min 
prevented VEGF-A- but not BK-induced permeability, confirming the role of VEGFR2 























receptor. Whole mount retinal staining showed that VEGF-A- and BK-induced 
permeability coincided with the phosphorylation of p38 on T180/Y182, its 
downstream effector HSP27 (on S82), as well as eNOS (on S1177) (Figure 2G, H).  
Phosphorylation of all three downstream effectors in response to VEGF-A but not BK 
was abolished following preincubation with SU-1498. 
This experimental model was also used for mouse retinae. Baseline permeability in 
mouse preparations was 0.15 ± 0.1x10-6 cm/s.  VEGF-A stimulation increased 
permeability to 0.65 ± 0.2x10-6 cm/s, and this was again sensitive to SU-1498 (Figure 
2I). Furthermore, we observed SU-1498-sensitive phosphorylation of p38, HSP27 
and eNOS in mouse retinal microvessels within 2 min of VEGF-A stimulation (Figure 
2J). To assess the compatibility of the ex vivo retina with knockdown technology, 
mouse eyes were injected intravitreously with siRNA against CLDN5. Western blot 
analysis of retinal lysates, harvested 72 h after the injection, showed that CLDN5 
expression was significantly reduced by 65% (Supplemental Figure 1C, D) and this 
was corroborated by whole mount staining of the retina (Supplemental Figure 1E). 
Microvessel permeability following knock-down of CLDN5 increased ca. 3-fold (to 
0.41±0.03 cm/s) (Supplemental Figure 1F, G). Taken together, these results 
demonstrated that the ex-vivo retinal preparation was a reliable model to measure 
retinal paracellular microvessel permeability in rats and mice.  
 
VEGF-A and Bradykinin induce AMPK phosphorylation 
In order to find new regulators of permeability, primary rat brain microvascular ECs 
were stimulated for 5 or 30 min with VEGF-A (50 ng/ml) from either the apical (non-
permeability inducing) or basal (permeability-inducing) side (Figure 3A) and cell 























stimulation many signalling components were phosphorylated, as exemplified by 
p38, HSP27, AMPK, eNOS, SRC, ERK and AKT (Figure 3B, C). 
Differentially phosphorylated proteins were categorised into three groups; group I 
phosphorylated only after basal stimulation with VEGF-A (such as p38, HSP27 and 
AMPK), group II phosphorylated regardless of the side of the stimulation (such as 
eNOS, SRC and ERK) and group III phosphorylated only when VEGF-A was applied 
apically (such as AKT). Phosphorylation of proteins exclusively in response to 
basally applied VEGF-A suggested they played a role in hyperpermeability (group I). 
Among these, AMPK stood out as its role in acute endothelial hyperpermeability has 
not yet been studied in detail. Additionally, AMPK was also among the 10 proteins, 
for which phosphorylation increased the most in response to basally applied VEGF-
A, when analysed by phospho-peptide mass spectrometry (Dragoni and Turowski, 
unpublished results). A previous study also demonstrates that AMPK link Ca2+ 
transients to VE-cad phosphorylation in response to ICAM-1 engagement in brain 
microvascular ECs (Martinelli et al., 2009). 
AMPK phosphorylation in response to VEGF-A was confirmed by Western blot 
analysis. Stimulation of primary rat brain ECs from the basal side led to rapid, 
transient phosphorylation of the catalytic subunit AMPKα on T172, which peaked 
after ca. 2 min (Figure 3D). A very similar activation pattern was observed in the 
intact rat retina when VEGF-A was applied directly to the top of the isolated retina 
(corresponding to the basal side of the endothelium) (Figure 3E).  BK induced similar 
phosphorylation of AMPKα T172, both in the cultured primary brain microvascular 
ECs and intact retina (Figure 3F, G). It was notable that AMPK phosphorylation was 
maximal after around 2 min in response to both VEGF-A and BK. However, BK 
























AMPK mediates VEGF-A/Bradykinin-induced permeability 
In order to specify the role of AMPK during VEGF-A- and BK-induced vascular 
permeability, AMPK activity was neutralised in the ex vivo retina. Preincubation of 
the ex-vivo retina with compound C, a widely used AMPK antagonist, significantly 
decreased VEGF-A- and BK- induced permeability by 80% and 93%, respectively 
(Figure 4A-D). Moreover, whole mount staining showed that pre-treatment with 
compound C prevented the VEGF-A- and BK-induced activation of p38, HSP27 and 
eNOS (Figures 4E, F).  
Brain and retinal endothelial cells express AMPKα1, but little to no α2 
(Vanlandewijck et al., 2018, Lipski et al., 2020). To assess neutralisation of AMPK 
more specifically, AMPKα1 was knocked down by intraocular injection of siRNA 72 h 
prior to preparing the retinae for further experimentation. Knocked-down retinae 
contained ca. 65% less AMPKα1 (Figures 4G-H), with a substantial loss in the 
vasculature detectable by immunohistochemistry (Figure 4I). AMPKα1 siRNA also 
reduced retinal AMPKα overall by ca. 70% (Supplemental figures 1H, I), indicating 
that α1 was the predominant isoform in the retina.  In AMPKα1 knocked-down 
retinae, neither VEGF-A nor BK stimulation led to significant permeability (Figures 
4J-M), or the phosphorylation of p38, HSP27 or eNOS (Figure 4N). 
Retinal endothelial cells express AMPK 1 and 2 (Lipski et al., 2020) and are thus 
susceptible to AMPK activation by a wide variety of molecules binding to its allosteric 
drug and metabolite (ADaM) site (Hardie, 2017). Stimulation of ex-vivo retinae with 
the 1 and 2 -specific PF739 and MK8722 (Figure 5A-D) and the reportedly less 
potent, 1-specific A769662 (Supplemental Figures 2A,B) led to instantaneous loss 























3-fold, respectively. All three compounds also induced substantial phosphorylation of 
AMPK, p38, HSP27 and eNOS in retinal microvessels within 2 min of stimulation 
(Figure 5E, Supplemental Figure 2E). In addition, 5-aminoimidazole-4-carboxamide 
riboside (AICAR), a classically used compound that, once inside cells, is 
phosphorylated to generate an AMP analogue with some specificity for AMPK (Kim 
et al., 2016), led to a similar increase in permeability and phosphorylation of AMPK, 
p38, HSP27 and eNOS (Supplemental Figures 2C-E). Taken together these results 
confirmed the central role of AMPK in VEGF-A- and BK-induced acute retinal 
leakage and showed that AMPK acted upstream of p38 and eNOS.  
 
VEGF-A- and BK-induced permeability requires Ca2+ and CAMKK, p38 and 
eNOS 
Next, we aimed at placing AMPK within established PIF signalling cascades. Ca2+ is 
critical for the activation of both p38 and eNOS (Takeda et al., 2004, Martinelli et al., 
2009, da Silva et al., 2009). To test its role in VEGF-A-induced vascular leakage, the 
ex-vivo retina was incubated with BAPTA, a Ca2+chelant, prior to VEGF-A 
administration. BAPTA treatment significantly reduced VEGF-A-induced permeability 
by 94%, and also prevented the phosphorylation of p38, HSP27 and eNOS (Figures 
6A, E), suggesting that Ca2+ acted upstream to these molecules. CAMKK is able to 
phosphorylate and activate AMPK in a Ca2+-dependent manner (Martinelli et al., 
2009, Hurley et al., 2005). Treatment of retinae with the CAMKK inhibitor STO-609 
significantly reduced VEGF-A-induced permeability by 86% and also prevented the 
activation of p38, HSP27 and eNOS (Figure 6B, E). The role of eNOS in permeability 
was re-confirmed by preincubation of the ex-vivo retinae with L-NAME, which 























HSP27 phosphorylation (Figure 6C, E), indicating that eNOS was not upstream of 
p38. Finally, the ex-vivo retina was preincubated with the p38 inhibitor SB203580, 
which significantly reduced the VEGF-A-induced permeability by 80% as well as 
activation of HSP27 but not of eNOS (Figure 6D, E).  
Similar results were obtained for BK-induced stimulation of retinae. BAPTA or STO 
nearly completely abolished BK-induced permeability, together with the activation of 
p38, HSP27 and eNOS (Figure 6F, G, J). Pre-treatment of the ex-vivo retina with L-
NAME reduced BK-induced permeability by 67% but did not affect p38 or HSP27 
phosphorylation (Figure 6H, J). Finally, SB203580 prevented BK-induced 
permeability as well as phosphorylation of HSP27 but not eNOS (Figure 6I, J).  
Importantly, VEGF-A- or BK-induced phosphorylation of AMPKα was completely 
abolished by BAPTA or STO. VEGF-A- but not BK-induced AMPKα phosphorylation 
was also abolished by SU1498 (Figure 7A). These results indicated that in the retina, 
VEGF-A and BK induced Ca2+ transients and consequent activation of AMPK via 
CAMKK. At this point signalling diverged into either activation of p38 or eNOS, which 
both contributed to permeability (Figure 7D). 
 
VEGF-A and BK stimulate VE-Cadherin phosphorylation 
Lastly, we wanted to analyse VE-cad internalisation in the VEGF-A and BK 
stimulated ex vivo retina. However, systematic correlation of cryo-immuno EM to 
leaky microvessels proved impractical. We therefore used phosphorylation of VE-cad 
on Y685 as a surrogate marker for retinal microvessel  permeability (Smith et al., 
2020), in particular since such VE-cad phosphorylation is also a prerequisite for 
internalisation after BK treatment (Orsenigo et al., 2012). VEGF-A or BK stimulation 























microvessels (Figure 7B). This phosphorylation was completely abolished following 
pre-incubation with compound C, L-NAME but not SB203580. The specific 
involvement of AMPK in VEGF-A- or BK-induced VE-cad phosphorylation was 
further confirmed in eyes injected intraocularly with AMPKα1-targetting siRNA 
(Figure 7C). Taken together these results showed that that VE-cad modulation was 
downstream of AMPK/eNOS but not AMPK/p38 (Figure 7D). Indeed, direct activation 
of ex vivo retinae with the NO donor DEANO also induced VE-cad phosphorylation 




Measuring retinal microvascular permeability has been mainly restricted to Miles-
type assays using either fluorescent tracers or Evans Blue/albumin (Radu and 
Chernoff, 2013, Canning et al., 2016). Chronic leakage can also be visualised in real 
time by fluorescein angiography (Couturier et al., 2019). However, collectively these 
methods, which measure the amount of extravasated tracer, do not only reflect the 
degree of leakage but are also strongly influenced by dye concentration in the 
vasculature and dye clearance from the tissue (Nagy et al., 2008, Turowski, 2017). 
Further disadvantages of these methods are that compound concentrations and 
timing cannot be controlled accurately. Thus, they are inadequate to measure acute 
permeability and associated signalling accurately and in a controlled manner. 
The ex-vivo retinal platform described herein addressed most of these issues. It 
constituted a significant advance to EC cultures, since it used a complete and intact 
neurovascular unit. The functionality of the retinal vasculature was preserved, with 























preparations of the brain and the retina also display full cellular functionality of e.g. 
pericytes (Mishra et al., 2014). Importantly, permeability to sulforhodamine-B was 
very low and within the range of that of other small non-ionic molecules at the intact 
BBB in vivo (Shi et al., 2014) and notably ca. 10 x lower than in preparations of pial 
microvessels (Easton et al., 1997), indicating that this model was highly suitable for 
permeability measurement at an intact neurovascular unit. Vascular barrier 
properties in these retinal explants was, as expected, dependent on tight junction 
integrity. The reported speed, at which compounds such as VEGF-A induce 
permeability (Bates, 2010), was fully recapitulated. Leakage measurements were 
then combined with whole tissue staining and analyses of the phosphorylation status 
of key mediators of permeability using phospho-specific antibodies to gain 
mechanistic insight. Furthermore, the preparations could be interrogated using small 
molecule antagonists and agonists at defined concentrations and times, and allowed 
for the identification of key downstream regulators, common to both VEGF-A and BK 
stimulation. Even more specific neutralisation of key proteins was achieved through 
prior intraocular injection of siRNA. Conceivably this model is compatible for use with 
genetically modified mice and disease models, further broadening its applicability. 
The ex vivo platform could also be used to measure Ca2+ transients or localised 
production of reactive oxygen or nitrogen species in response to vasoactive 
compounds such as VEGF-A or BK.  
Measurements in retinae were done ex vivo, in the absence of blood flow. Blood flow 
and associated shear stress may influence EC biology, such as cell-cell adhesion 
and inflammatory dysfunction (Orsenigo et al., 2012, Chistiakov et al., 2017, Ho et 
al., 2019) and their absence in our preparation must be taken into account when 























shear stress appears to be remembered in ECs in vitro for at least 24 h (Walsh et al., 
2011). 
For the purpose of developing and validating the ex vivo retinal platform we have 
focused on PIFs, which induce permeability when added to the abluminal (tissue) 
side of the endothelium, such as VEGF-A and BK (Hudson et al., 2014), as these are 
readily applied on top of the retinal explants. Other PIFs that act only from the 
luminal side, such as lysophosphatidic acid (Hudson et al., 2014) or 
lysophosphatidylcholine (Canning et al., 2016), could also potentially be investigated 
in this system. However, this would require the use of a manifold injection system 
(Liu et al., 2000), which allows switching between injection of sulforhodamine-B with 
or without permeability factor into radial vessels.  
VEGF-A and BK induced acute leakage in retinal microvessels, which was 
associated with and dependent on Ca2+, the MAPK p38 and eNOS, in agreement 
with published data (Wu et al., 1999, Hudson et al., 2014, Di Lorenzo et al., 2013). 
We also identified AMPK, specifically its catalytic subunit isoform 1, as a novel key 
mediator of both VEGF-A- and BK-induced permeability, indicating it is a core 
regulator of acute vascular permeability.  AMPK is primarily known to regulate 
energy requirements of the cell, but has also been implicated in other seemingly 
unrelated cellular processes such as migration, cell growth and apoptosis (Hardie, 
2011). This protein kinase has been studied before in relation to its protective role of 
the BBB, in particular when challenged by LPS (Takata et al., 2013, Zhao et al., 
2014, Ange et al., 2020), whereas in the retinal pigment epithelium it has been 
shown to be responsible for permeability induced by IL-1β (Villarroel et al., 2011). 
However, all these studies address chronic changes and do not focus on the role of 























AMP: ATP concentrations and phosphorylation on T172 by LKB1, we found that, in 
the regulation of endothelial permeability, AMPK was activated downstream of Ca2+ 
and CAMKK. This activation pathway has previously been described as non-
canonical (Carling et al., 2008) and is also operational when CNS ECs facilitate the 
transmigration of lymphocytes (Martinelli et al., 2009). Notably, VEGF-A has also 
been reported before to induce NO production via a pathway requiring Ca2+ and 
AMPK (Reihill et al., 2007). Indeed, eNOS phosphorylation on S1177 can be 
mediated by AKT (Fulton et al., 1999) or AMPK (Martinelli et al., 2009, Youn et al., 
2009). However, the PI3K/Akt pathway is not relevant for VEGF-A-induced 
permeability in neurovascular ECs (Hudson et al., 2014). We confirmed the 
phosphorylation of eNOS on S1177 downstream of AMPK both during VEGF-A and 
BK permeability induction. Notably, the Ca2+/AMPK/eNOS pathway resulted in the 
phosphorylation of VE-cad on Y685, identified previously as key for vascular 
permeability in the periphery (Orsenigo et al., 2012) and the retina (Smith et al., 
2020), thus providing a direct link between AMPK and paracellular junction 
regulation. Whilst in our system NO-induced VE-cad phosphorylation was sensitive 
to the soluble guanylyl cyclase inhibitor ODQ (Supplemental Figure 3A), suggesting 
a connecting role for cGMP/protein kinase G, adherens junction complexes also 
appear to be direct targets of NO during permeability induction, namely through S-
nitrosylation of -catenin and its subsequent dissociation from VE-cad (Thibeault et 
al., 2010). Further research is required to determine how protein kinase G and direct 
S-nitrosylation processes are functionally linked to the tyrosine phosphorylation and 
internalisation of VE-cad. For retinal permeability, occludin phosphorylation and 
internalisation also plays an important role. However, judging from the published 























thus either secondary to VE-cad phosphorylation or, with its dependency on PKC  
activation, outside of the signalling network we have investigated here (Murakami et 
al., 2012). 
In response to VEGF-A and BK, AMPK also regulated the phosphorylation of the 
MAPK p38 and its substrate HSP27, both previously implicated in actin 
rearrangement during endothelial barrier disruption (Sawada et al., 2015, Kasa et al., 
2015, Hirano et al., 2004). P38 is a bona fide regulator of VEGF-A responses (Corre 
et al., 2017) and its activation downstream of cdc42 and p21-activated protein kinase 
(PAK) and subsequent modulation of the actin cytoskeleton occurs during VEGF-A-
induced endothelial migration downstream of VEGFR2 phosphorylation on Y1214 
(Lamalice et al., 2004). PAK1 also regulates VEGF-induced permeability in cultured 
mouse endothelial cells, possibly through direct phosphorylation of VE-cad (Gavard 
and Gutkind, 2006). However, in the VEGF-A- or PF739-stimulated ex vivo retina, 
neither permeability induction nor the phosphorylation of p38 were blocked by 
FRAX597, a potent group I PAK inhibitor (Han et al., 2020). This points to potentially 
important molecular differences between permeability regulation in neural and non-
neural endothelium. In the absence of evidence for a role of PAK, we favour an 
alternative model of direct activation of p38 by AMPK via TAB1, a pathway described 
in apoptotic lymphocytes and the ischemic heart (Li et al., 2005, Lanna et al., 2014). 
By switching between two different p38 activation modes (Ca2+/AMPK/TAB1 versus 
cdc42/PAK) ECs could adapt cytoskeletal regulation to the specific requirement of 
EC migration or permeability. However, this model requires thorough future analysis 
with specific focus on all endothelially expressed PAK and TAB isoforms. 
The ex-vivo retina proved to be a reliable model and demonstrated its usefulness in 























such a key regulator, it is unlikely to be exploitable as a target for anti-leakage 
treatments: its central role in regulating cellular energy demands throughout the body 
hints at many potential side effects. Activation of AMPK is currently investigated as a 
therapeutic option to treat cancer, metabolic syndrome and diabetes (Hardie, 2017, 
Kim et al., 2016). However, in light of the strong induction of permeability we 
observed in response to at least two AMPK agonists, we propose that these avenues 
should be explored cautiously, since at least acute microvascular leakage may 
accompany such treatment modalities. Nevertheless, our data collectively indicated 
that the ex vivo retina platform can play an important part in elucidating mechanisms 
and signalling of neurovascular leakage. 
 
 
MATERIALS AND METHODS 
Materials 
Recombinant rat VEGF-A (165) was purchased from R&D Systems (Abingdon, 
United Kingdom). Bradykinin, Sulforhodamine-B, Evans blue, SU-1498, SB-203580, 
Compound-C, STO-609, L-NG-Nitro arginine methyl ester (L-NAME), BAPTA-AM, 5-
Aminoimidazole-4-carboxamide ribonucleotide (AICAR), A769662, 
Diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEANO) and 
1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) were purchased from MERCK 
(Dorset, United Kingdom). PF739 was purchased from AOBIOUS (Gloucester, USA). 
MK8722 was purchased from Cambridge Biosciences (Cambridge, UK). FRAX597 
was purchased from Stratech Scientific Ltd (Ely, UK). Polyclonal antibodies specific 
for p38, HSP27, AMPKα, eNOS and their phosphorylated forms (p38 Thr180/Tyr182, 























Technology (Beverly, MA). Recombinant Anti-AMPK alpha 1 antibody was from 
Abcam (Cambridge, UK). Polyclonal antibodies against phosphorylated VE-cad (p-
Y658-VEC and p-Y685-VEC) were a gift from E. Dejana (Milan, Italy). 
 
Animals 
Wistar female rats (7-10 weeks old) and C75BL/6J mice (7-12 weeks old) were 
purchased from Charles River Laboratories. All animal procedures were performed 
in accordance with Animal Welfare Ethical Review Body (AWERB) and Association 
for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals 
in Ophthalmic and Vision Research guidelines and under a UK Home Office licence. 
 
Methods 
Brain microvascular EC isolation and culture 
Microvessels were isolated from rat cortical grey matter by collagenase dispase 
digestion and BSA and Percoll density gradient centrifugation (Hudson et al., 2014). 
Purified vessels were seeded onto collagen IV/fibronectin-coated Costar Transwells 
(Fisher Scientific) at high density (vessels from 6 rat brains per 40 cm2). Cells were 
grown in EGM2-MV (Lonza), with 5 mg/ml puromycin from the second day for 3 
days, for 2–3 weeks until their TEER plateaued at values above 200 Ω.cm2. 
The human brain MVEC line hCMEC/D3 was also grown in EGM2-MV as previously 

























Transendothelial Electrical Resistance (TEER) 
Changes in the TEER were determined by time-resolved impedance spectroscopy of 
primary cerebral rat brain microvascular ECs grown on 12 mm Transwells, using a 
CellZscope (Nanoanalytics). Before the addition of VEGF-A and BK, TEER values 
were 500-800 Ω.cm2. 
 
Immunocytochemistry 
Primary cerebral rat brain microvascular ECs were fixed with methanol (−20°C). 
Staining was performed as previously described using antibodies against occludin 
(OC-3F10, Invitrogen) (Turowski et al., 2004) or VE-cad (Martins et al., 2013). 
 
Immunogold Electron Microscopy 
Cryo-immuno electron microscopy (EM) was performed as previously 
described(Hudson et al., 2014). Briefly, hCMEC/D3 cells were fixed in 4% PFA and 
0.1% glutaraldehyde. Sections were stained using antibodies against the 
extracellular domain (TEA 1.31; Serotech) or the C terminus (sc-6458; Santa Cruz) 
of VE-cad. Image J (NIH) was used to process images and measure the distance 
among the gold particles and the interendothelial junctions. 
 
Retinal explant preparation 
Retinal explants were prepared essentially as described before (Warboys et al., 
2009). A Wistar female rats or C75BL/6J mouse was killed by overdose of CO2. The 
common carotid artery was carefully exposed and cannulated with a glass 























(300U/L heparin in 0.9% NaCl. Mouse: 5 ml; rat: 20 ml), then with stabilizing solution 
(10 mM Mg2+, 110 mM NaCl, 8 mMKCl, 10 mM HEPES, 1 mM CaCl2, pH 7.0. 10 µM 
Isoproterenol to be added before use. Mouse: 5 ml; rat: 20 ml), also referred to as 
cardioplegic solution containing isoproterenol, and finally with the same solution 
supplemented with 5 g/L Evans blue dye in 10% albumin (mouse: 5 ml; rat: 20 ml) 
for subsequent visualisation of the vasculature. Next, an eye was surgically removed 
and and the retina isolated, together with the attached sclera. The retina was 
flattened onto a transparent silicone medium (SYLGARD® 184 SILICONE 
ELASTOMER KIT by Dow Corning), kept in position by a metal ring, and the 
resulting well sealed by grease. Throughout the procedure the retina was 
continuously superfused with Krebs solution (124 mM sodium chloride, 5 mM 
potassium chloride, 2 mM MgSO4, 0.125 mM NaH2 PO4, 22 mM NaHCO3, 2 mM 
CaCl2, pH 7.4. 5 mM glucose and 0.1% BSA to be added before use). 
 
Permeability measurements 
Retinal explants were mounted for visualisation and further experimentation on an 
upright Zeiss Axiophot fluorescent microscope. A radial vessel of a superfused 
retinal explant was cannulated at ca. 150 μm from the optic nerve using a 
microinjection needle (tip diameter 1-5 m, sharpened to a bevel of < 30 ) and the 
entire retinal vasculature injected with sulforhodamine-B (1 mg/ml in Krebs solution). 
Illumination was switched to fluorescence and the vessels were visualized under a 
TRITC filter using a Olympus 40X water immersion objective. For permeability 
measurements a microvessel was chosen at least 200 µm away from the cannulated 
radial vessel. Fluorescent content of the vessel was recorded continuously by time 























recorded for ca. 30 s, before VEGF-A or BK (in Krebs solution) was added on the top 
of the retina. Time lapse series were analysed using ImageJ. Time-dependent 
fluorescence intensity data of the chosen vessel was derived from a square region of 
interest (ca. 18 x 18 pixels) (Supplemental Figure 1a and b). Fluorescence in the 
immediate vicinity of the microvessel was measured and subtracted from the vessel 
fluorescence measurements. Pixel intensity measurements were charted against 
time, and permeability values were computed by fitting data to the exponential 
equation Ct = C0*e
-kt, where k = 4P/d and d is the diameter of the vessel (Hudson et 
al., 2014).  The difference in permeability between pre-treatment and post-treatment 
resulted in the absolute permeability change associated with the treatment regimen. 
 
Immunohistochemistry 
After dissection, retinae from rat or mouse were fixed with 4% PFA at room 
temperature for 1 h. After 30 min of blocking (3% Triton X-100, 1% Tween, 0.5% 
Bovine Serum Albumin in 2x PBS), retinae were incubated with primary antibodies 
against Isolectin B4 (IB-4), P-p38, P-HSP27, P-eNOS, P-AMPKα, claudin-5 and P-
VE-Cadherin at 4 ºC o/n. Retinae were washed and incubated with matching Alexa 
Fluor conjugated secondary antibodies at room temperature for 2 h. Finally, retinae 
were washed and mounted using Mowiol 4-88 mounting medium (Sigma). More 
details can be found in ref (Hudson et al., 2014). 
 
siRNA-mediated Knockdown of claudin-5 and AMPKα 
Specific SiRNA sequences targeting claudin-5 or the α subunit of AMPK were 
purchased from Dharmacon (Chicago, IL). Mice were anesthetised by intraperitoneal 























sterile water.  2 µl of the siRNA (1ng/ml in sterile PBS) were injected intravitreously 
in the right eye under a stereomicroscope, using a Hamilton syringe with a 3 degrees 
Hamilton RN needle (Esslab). Two microliters of scrambled siRNA were injected into 
the left eye as a control.  To inject, an initial puncture was made to the superior nasal 
sclera, at the level of the pars plana. Then, the tip of the needle was further 
introduced through the puncture hole with a 45-degree angle into the vitreous body. 
Retinae were isolated 72 h after the injection. 
 
Phosphoantibody array 
Mature monolayers of primary, unpassaged brain microvascular ECs grown on 24 
mm Costar Transwells were stimulated with VEGF-A (50 ng/ml) from the apical or 
basal side for 5 or 30 min. Cells from 2 Transwells were combined by lysis in 200 µL 
of lysis buffer and subjected to screening using Human Phospho-Kinase Array 
Proteome Profiler Array (R&D Systems; ARY003B) exactly according to the 
manufacturer’s instructions. Arrays were exposed for varying amounts of time to 
capture signals in the linear range and quantified by densitometric scanning and 
ImageJ (NIH). Signals were normalised using array-internal controls. Results were 
expressed as fold-differences between apical versus basal signals. 
 
Western Blots 
Cell lysates were prepared as previously described(Hudson et al., 2014). Proteins 
were separated by SDS-PAGE and transferred to nitrocellulose by semidry 
electrotransfer. Membranes were blocked o/n and then incubated with the 
appropriate antibody diluted at 1:2,000. Membranes were washed three times with 























conjugated IgG (GE Healthcare) at a dilution of 1:10,000 and 1:5,000, respectively. 
Membranes were developed using the ECL reagents (Roche) and exposed to X-ray 
film. Protein bands were evaluated by densitometric quantification, normalized 
against the amount of total protein, and GADPH or Tubulin. A selection of raw blots 
is shown in the supplementary information. 
 
Statistics 
For each experiment a protocol was written following careful consideration of the 
total number of animals/samples and group sizes required to realistically achieve the 
objectives based on both relevant publications and previous experience of the model 
used. Accordingly, we performed power (0.8) calculations 
(http://powerandsamplesize.com) to determine the anticipated number of 
animals/samples needed. These were discussed with an in–house statistician. 
Generally, the statistical model used was ANOVA (pairwise, 2-sided equality). Effect 
size and SD were guided by our previous extensive accumulated data. We aimed to 
achieve a significance level of 5% and a power of 80% to minimize the number of 
animals per experimental group. All raw data was used for analyses. If the 
morphological integrity of tissue explants appeared compromised, no further 
experiments were performed with such samples. All attempts of replication were 
successful, and the data shown represents mean/aggregate data from all 
replications. Explants from mice or rat were randomly assigned to an experimental 
protocol. Each experiment on a single tissue explant consisted of a treatment and an 
appropriate control. Image analyses were done by different experimenters, who did 

























TEER measurements of three independent cell monolayers were combined and 
expressed as mean ± SD. Significant differences were determined by two ways 
ANOVA with replication, with significance levels set at 0,05, followed by post-hoc 
Bonferroni’s multiple comparison test. 
Distances of VE-cad immunogold complexes were measured in electron 
micrographs from three independent preparations, averaged and expressed as 
mean ± SD. Significant differences were determined by one-way ANOVA with 
significance levels set at 0.05, followed by post-hoc Dunnett's tests.  
Densitometric quantification of three independent immunoblots were determined by 
changes in protein or phosphoprotein content normalized to tubulin or GADPH/total 
protein loading controls, with values expressed as fold increase. Data were 
presented as mean ± SD. Statistics were performed using one-way ANOVA with 
significance levels set at 0.05, followed by post-hoc Dunnett's tests.  
Permeability measurements from at least 3 different ex vivo retinal preparations were 
combined and expressed as mean ± SD. Significant differences were determined via 
t-test between the control and each inhibitor.  




























We thank Dr Paul Fraser (King's College London) for introducing us to his early ex-
vivo retinal preparations and Prof. John Greenwood (UCL) for critical comments on 
the manuscript. siRNAs targeting CLDN5 were kindly provided by Dr Matthew 
Campbell (Trinity College Dublin). Phospho-VE-Cad antibodies were kindly provided 
by Dr Fabrizio Orsenigo and Prof. Elisabetta Dejana (FIRC Institute of Molecular 
Oncology, Milan and Uppsala University). 
This work was supported by a Moorfields Eye Charity grant to S.D. and a Diabetes 
UK grant to P.T. 
 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request. 
 






























AUTHOR CONTRIBUTION STATEMENT 
S.D.: designed experiments; performed experiments; analysed the data; wrote the 
manuscript 
B.C.; E.K.; T.B; M.H.S.: performed experiments 
P.T.: designed experiments; performed experiments; analysed the data; wrote the 
manuscript 




























ANGE, M., CASTANARES-ZAPATERO, D., DE POORTERE, J., DUFEYS, C., COURTOY, G. E., BOUZIN, C., 
QUARCK, R., BERTRAND, L., BEAULOYE, C. & HORMAN, S. 2020. alpha1AMP-Activated 
Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption 
via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway. Int J Mol Sci, 
21. 
BATES, D. O. 2010. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res, 
87, 262-71. 
BROWN, D. M., NGUYEN, Q. D., MARCUS, D. M., BOYER, D. S., PATEL, S., FEINER, L., SCHLOTTMANN, 
P. G., RUNDLE, A. C., ZHANG, J., RUBIO, R. G., ADAMIS, A. P., EHRLICH, J. S., HOPKINS, J. J., 
RIDE & GROUP, R. R. 2013. Long-term outcomes of ranibizumab therapy for diabetic macular 
edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology, 120, 
2013-22. 
CAMPOCHIARO, P. A. & PETERS, K. G. 2016. Targeting Tie2 for Treatment of Diabetic Retinopathy 
and Diabetic Macular Edema. Curr Diab Rep, 16, 126. 
CANNING, P., KENNY, B. A., PRISE, V., GLENN, J., SARKER, M. H., HUDSON, N., BRANDT, M., LOPEZ, F. 
J., GALE, D., LUTHERT, P. J., ADAMSON, P., TUROWSKI, P. & STITT, A. W. 2016. Lipoprotein-
associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal 
vasopermeability during diabetes. Proc Natl Acad Sci U S A, 113, 7213-8. 
CARLING, D., SANDERS, M. J. & WOODS, A. 2008. The regulation of AMP-activated protein kinase by 
upstream kinases. Int J Obes (Lond), 32 Suppl 4, S55-9. 
CHISTIAKOV, D. A., OREKHOV, A. N. & BOBRYSHEV, Y. V. 2017. Effects of shear stress on endothelial 
cells: go with the flow. Acta Physiol (Oxf), 219, 382-408. 
CLAESSON-WELSH, L., DEJANA, E. & MCDONALD, D. M. 2020. Permeability of the Endothelial Barrier: 
Identifying and Reconciling Controversies. Trends Mol Med. 
CORRE, I., PARIS, F. & HUOT, J. 2017. The p38 pathway, a major pleiotropic cascade that transduces 
stress and metastatic signals in endothelial cells. Oncotarget, 8, 55684-55714. 
COUTURIER, A., REY, P. A., ERGINAY, A., LAVIA, C., BONNIN, S., DUPAS, B., GAUDRIC, A. & TADAYONI, 
R. 2019. Widefield OCT-Angiography and Fluorescein Angiography Assessments of 
Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial 
Growth Factor. Ophthalmology. 
DA SILVA, C. G., SPECHT, A., WEGIEL, B., FERRAN, C. & KACZMAREK, E. 2009. Mechanism of 
purinergic activation of endothelial nitric oxide synthase in endothelial cells. Circulation, 119, 
871-9. 
DI LORENZO, A., LIN, M. I., MURATA, T., LANDSKRONER-EIGER, S., SCHLEICHER, M., KOTHIYA, M., 
IWAKIRI, Y., YU, J., HUANG, P. L. & SESSA, W. C. 2013. eNOS-derived nitric oxide regulates 
endothelial barrier function through VE-cadherin and Rho GTPases. J Cell Sci, 126, 5541-52. 
EASTON, A. S., SARKER, M. H. & FRASER, P. A. 1997. Two components of blood-brain barrier 
disruption in the rat. J Physiol, 503 ( Pt 3), 613-23. 
FORD, J. A., LOIS, N., ROYLE, P., CLAR, C., SHYANGDAN, D. & WAUGH, N. 2013. Current treatments in 
diabetic macular oedema: systematic review and meta-analysis. BMJ Open, 3. 
FULTON, D., GRATTON, J. P., MCCABE, T. J., FONTANA, J., FUJIO, Y., WALSH, K., FRANKE, T. F., 
PAPAPETROPOULOS, A. & SESSA, W. C. 1999. Regulation of endothelium-derived nitric oxide 
production by the protein kinase Akt. Nature, 399, 597-601. 
GAVARD, J. & GUTKIND, J. S. 2006. VEGF controls endothelial-cell permeability by promoting the 























HAN, D., WANG, H., CUI, W., ZHANG, B. & CHEN, B. Z. 2020. Computational insight into the 
mechanisms of action and selectivity of Afraxis PAK inhibitors. Future Med Chem, 12, 367-
385. 
HARDIE, D. G. 2011. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell 
function. Genes Dev, 25, 1895-908. 
HARDIE, D. G. 2017. Targeting an energy sensor to treat diabetes. Science, 357, 455-456. 
HARDIE, D. G. 2018. Keeping the home fires burning: AMP-activated protein kinase. J R Soc Interface, 
15. 
HIRANO, S., REES, R. S., YANCY, S. L., WELSH, M. J., REMICK, D. G., YAMADA, T., HATA, J. & GILMONT, 
R. R. 2004. Endothelial barrier dysfunction caused by LPS correlates with phosphorylation of 
HSP27 in vivo. Cell Biol Toxicol, 20, 1-14. 
HO, R. X., TAHBOUB, R., AMRAEI, R., MEYER, R. D., VARONGCHAYAKUL, N., GRINSTAFF, M. W. & 
RAHIMI, N. 2019. The cell adhesion molecule IGPR-1 is activated by, and regulates responses 
of endothelial cells to shear stress. J Biol Chem. 
HUDSON, N., POWNER, M. B., SARKER, M. H., BURGOYNE, T., CAMPBELL, M., OCKRIM, Z. K., 
MARTINELLI, R., FUTTER, C. E., GRANT, M. B., FRASER, P. A., SHIMA, D. T., GREENWOOD, J. & 
TUROWSKI, P. 2014. Differential apicobasal VEGF signaling at vascular blood-neural barriers. 
Dev Cell, 30, 541-52. 
HURLEY, R. L., ANDERSON, K. A., FRANZONE, J. M., KEMP, B. E., MEANS, A. R. & WITTERS, L. A. 2005. 
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase 
kinases. J Biol Chem, 280, 29060-6. 
KASA, A., CSORTOS, C. & VERIN, A. D. 2015. Cytoskeletal mechanisms regulating vascular endothelial 
barrier function in response to acute lung injury. Tissue Barriers, 3, e974448. 
KIM, J., YANG, G., KIM, Y., KIM, J. & HA, J. 2016. AMPK activators: mechanisms of action and 
physiological activities. Exp Mol Med, 48, e224. 
KITA, T., CLERMONT, A. C., MURUGESAN, N., ZHOU, Q., FUJISAWA, K., ISHIBASHI, T., AIELLO, L. P. & 
FEENER, E. P. 2015. Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of 
Diabetic Macular Edema. Diabetes, 64, 3588-99. 
KLAASSEN, I., VAN NOORDEN, C. J. & SCHLINGEMANN, R. O. 2013. Molecular basis of the inner 
blood-retinal barrier and its breakdown in diabetic macular edema and other pathological 
conditions. Prog Retin Eye Res, 34, 19-48. 
LAMALICE, L., HOULE, F., JOURDAN, G. & HUOT, J. 2004. Phosphorylation of tyrosine 1214 on 
VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. 
Oncogene, 23, 434-45. 
LANNA, A., HENSON, S. M., ESCORS, D. & AKBAR, A. N. 2014. The kinase p38 activated by the 
metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat 
Immunol, 15, 965-72. 
LI, J., MILLER, E. J., NINOMIYA-TSUJI, J., RUSSELL, R. R., 3RD & YOUNG, L. H. 2005. AMP-activated 
protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of 
p38 MAPK to TAB1 in the ischemic heart. Circ Res, 97, 872-9. 
LIPSKI, D. A., FOUCART, V., DEWISPELAERE, R., CASPERS, L. E., DEFRANCE, M., BRUYNS, C. & 
WILLERMAIN, F. 2020. Retinal endothelial cell phenotypic modifications during experimental 
autoimmune uveitis: a transcriptomic approach. BMC Ophthalmol, 20, 106. 
LIU, B., SHAO, Y. & MIRKIN, M. V. 2000. Dual-pipet techniques for probing ionic reactions. Anal 
Chem, 72, 510-9. 
MARTINELLI, R., GEGG, M., LONGBOTTOM, R., ADAMSON, P., TUROWSKI, P. & GREENWOOD, J. 
2009. ICAM-1-mediated endothelial nitric oxide synthase activation via calcium and AMP-
























MARTINS, T., BURGOYNE, T., KENNY, B. A., HUDSON, N., FUTTER, C. E., AMBROSIO, A. F., SILVA, A. P., 
GREENWOOD, J. & TUROWSKI, P. 2013. Methamphetamine-induced nitric oxide promotes 
vesicular transport in blood-brain barrier endothelial cells. Neuropharmacology, 65, 74-82. 
MISHRA, A., O'FARRELL, F. M., REYNELL, C., HAMILTON, N. B., HALL, C. N. & ATTWELL, D. 2014. 
Imaging pericytes and capillary diameter in brain slices and isolated retinae. Nat Protoc, 9, 
323-36. 
MURAKAMI, T., FREY, T., LIN, C. & ANTONETTI, D. A. 2012. Protein kinase cbeta phosphorylates 
occludin regulating tight junction trafficking in vascular endothelial growth factor-induced 
permeability in vivo. Diabetes, 61, 1573-83. 
NAGY, J. A., BENJAMIN, L., ZENG, H., DVORAK, A. M. & DVORAK, H. F. 2008. Vascular permeability, 
vascular hyperpermeability and angiogenesis. Angiogenesis, 11, 109-19. 
ORSENIGO, F., GIAMPIETRO, C., FERRARI, A., CORADA, M., GALAUP, A., SIGISMUND, S., RISTAGNO, 
G., MADDALUNO, L., KOH, G. Y., FRANCO, D., KURTCUOGLU, V., POULIKAKOS, D., BALUK, P., 
MCDONALD, D., GRAZIA LAMPUGNANI, M. & DEJANA, E. 2012. Phosphorylation of VE-
cadherin is modulated by haemodynamic forces and contributes to the regulation of 
vascular permeability in vivo. Nat Commun, 3, 1208. 
RADU, M. & CHERNOFF, J. 2013. An in vivo assay to test blood vessel permeability. J Vis Exp, e50062. 
REIHILL, J. A., EWART, M. A., HARDIE, D. G. & SALT, I. P. 2007. AMP-activated protein kinase 
mediates VEGF-stimulated endothelial NO production. Biochem Biophys Res Commun, 354, 
1084-8. 
SAWADA, J., LI, F. & KOMATSU, M. 2015. R-Ras Inhibits VEGF-Induced p38MAPK Activation and 
HSP27 Phosphorylation in Endothelial Cells. J Vasc Res, 52, 347-59. 
SHI, L., ZENG, M., SUN, Y. & FU, B. M. 2014. Quantification of blood-brain barrier solute permeability 
and brain transport by multiphoton microscopy. J Biomech Eng, 136, 031005. 
SMITH, R. O., NINCHOJI, T., GORDON, E., ANDRE, H., DEJANA, E., VESTWEBER, D., KVANTA, A. & 
CLAESSON-WELSH, L. 2020. Vascular permeability in retinopathy is regulated by VEGFR2 
Y949 signaling to VE-cadherin. Elife, 9. 
SWEENEY, M. D., ZHAO, Z., MONTAGNE, A., NELSON, A. R. & ZLOKOVIC, B. V. 2019. Blood-Brain 
Barrier: From Physiology to Disease and Back. Physiol Rev, 99, 21-78. 
TAKATA, F., DOHGU, S., MATSUMOTO, J., MACHIDA, T., KANESHIMA, S., MATSUO, M., SAKAGUCHI, 
S., TAKESHIGE, Y., YAMAUCHI, A. & KATAOKA, Y. 2013. Metformin induces up-regulation of 
blood-brain barrier functions by activating AMP-activated protein kinase in rat brain 
microvascular endothelial cells. Biochem Biophys Res Commun, 433, 586-90. 
TAKEDA, K., MATSUZAWA, A., NISHITOH, H., TOBIUME, K., KISHIDA, S., NINOMIYA-TSUJI, J., 
MATSUMOTO, K. & ICHIJO, H. 2004. Involvement of ASK1 in Ca2+-induced p38 MAP kinase 
activation. EMBO Rep, 5, 161-6. 
TAKESHI NINCHOJI, D. T. L., ROSS O. SMITH, MARIE HEDLUND, DIETMAR VESTWEBER, WILLIAM C. 
SESSA, LENA CLAESSON-WELSH 2020. eNOS-induced vascular barrier disruption in 
retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin. bioRxiv. 
THIBEAULT, S., RAUTUREAU, Y., OUBAHA, M., FAUBERT, D., WILKES, B. C., DELISLE, C. & GRATTON, J. 
P. 2010. S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced 
endothelial cell permeability. Mol Cell, 39, 468-76. 
TUROWSKI, P. 2017. Leakage at Blood-Neural Barriers. In: LINK, S. (ed.) The Blood Brain Barrier and 
Inflammation. 
TUROWSKI, P., ADAMSON, P., SATHIA, J., ZHANG, J. J., MOSS, S. E., AYLWARD, G. W., HAYES, M. J., 
KANUGA, N. & GREENWOOD, J. 2004. Basement membrane-dependent modification of 
phenotype and gene expression in human retinal pigment epithelial ARPE-19 cells. Invest 
Ophthalmol Vis Sci, 45, 2786-94. 
VANLANDEWIJCK, M., HE, L., MAE, M. A., ANDRAE, J., ANDO, K., DEL GAUDIO, F., NAHAR, K., 























MOCHIZUKI, N., KELLER, A., LENDAHL, U. & BETSHOLTZ, C. 2018. A molecular atlas of cell 
types and zonation in the brain vasculature. Nature, 554, 475-480. 
VILLARROEL, M., GARCIA-RAMIREZ, M., CORRALIZA, L., HERNANDEZ, C. & SIMO, R. 2011. Fenofibric 
acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by 
suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia, 54, 1543-53. 
WALSH, T. G., MURPHY, R. P., FITZPATRICK, P., ROCHFORT, K. D., GUINAN, A. F., MURPHY, A. & 
CUMMINS, P. M. 2011. Stabilization of brain microvascular endothelial barrier function by 
shear stress involves VE-cadherin signaling leading to modulation of pTyr-occludin levels. J 
Cell Physiol, 226, 3053-63. 
WARBOYS, C. M., TOH, H. B. & FRASER, P. A. 2009. Role of NADPH oxidase in retinal microvascular 
permeability increase by RAGE activation. Invest Ophthalmol Vis Sci, 50, 1319-28. 
WEIDERT, E., POHLER, S. E., GOMEZ, E. W. & DONG, C. 2014. Actinomyosin contraction, 
phosphorylation of VE-cadherin, and actin remodeling enable melanoma-induced 
endothelial cell-cell junction disassembly. PLoS One, 9, e108092. 
WEKSLER B. B., S. E. A., PERRIÈRE N., CHARNEAU P., HOLLOWAY K., LEVEQUE M., TRICOIRE-LEIGNEL 
H., NICOTRA A., BOURDOULOUS S, TUROWSKI P., MALE D. K., ROUX F., GREENWOOD J., 
ROMERO I. A., AND COURAUD P. O. 2005. Blood-brain barrier-specific properties of a human 
adult brain endothelial cell line. FASEB J, 19, 1872–1874. 
WU, H. M., YUAN, Y., ZAWIEJA, D. C., TINSLEY, J. & GRANGER, H. J. 1999. Role of phospholipase C, 
protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Physiol, 276, 
H535-42. 
YOUN, J. Y., WANG, T. & CAI, H. 2009. An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade 
mediating VEGF-dependent endothelial nitric oxide production. Circ Res, 104, 50-9. 
ZHAO, Z., HU, J., GAO, X., LIANG, H. & LIU, Z. 2014. Activation of AMPK attenuates 
lipopolysaccharide-impaired integrity and function of blood-brain barrier in human brain 





















































Figure 1. VEGF-A and BK induced permeability in cultured brain microvascular 
ECs.  
(A, B) Primary rat brain microvascular ECs were grown on permeable Transwell 
inserts to confluence and until they reached full electrical barrier (500-800 Ω.cm2). 
VEGF-A (A) or BK (B) were added at time 0. Shown are means ± SD of normalized 
resistance changes (n=3). Significant changes were detected in the short- and long-
term, as well as the overall responses. (C) Changes in the distribution of VE-Cad 
and Occludin in response to basal (corresponding to abluminal) stimulation with 
VEGF-A or BK were analysed by confocal microscopy in post-confluent primary rat 
brain microvascular ECs. Whites arrows indicate the broadening of the VE-Cad 
staining. Scale bar, 10 μM. (D-F) Cryo-immuno-EM of VE-Cad distribution in control 
(D) and VEGF-A (E) or BK (F) stimulated human hCMEC/D3 cells. Shown are 
interendothelial junction areas with the two adjacent membranes (red arrowheads). 
White arrowheads point to gold labelled VE-Cad, which in control cells was found 
predominantly associated with abutting plasma membranes (within 20 nm; i.e. the 
distance expected by the primary and the secondary bridging Ab). Scale bar, 100 
nm. (G) Box and whisker plot of distances of VE-Cad gold particles from cell-cell 
junctions as determined from three independent preparations as shown in (D-F). 

























Figure 2. Validation of the ex vivo retina model in rats.  
(A, B) Control retinae were from animals directly perfused fixed with 4% PFA. Ex 
vivo retinae were isolated as described, flat mounted and left submerged with Krebs 
solutions for 1 h before PFA fixation. Whole mounts were stained for Isolectin B4 
(IB4), claudin-5 (CLDN5) and VE-cad as indicated. (C-F) Sulforhodamine-B 
fluorescent intensities were recorded in single retinal capillaries. 50 ng/ml VEGF-A 
(C, D) or 10 μM Bradykinin (BK) (E, F) were applied on top of the retina (abluminal 
side) at times indicated. Optionally retinae were preincubated with the VEGFR2-
selective antagonist SU1498 (10 μM) for 15 min prior to recording. Independent data 
points and mean (± SD) permeability changes are shown in (D) and (F). (G, H) Ex 
vivo retinal explants were incubated with VEGF-A (G) or BK (H) for 2 min, fixed using 
4% PFA and then stained using IB4 (green) and for phospho-p38 (pT180/Y182), 
phospho-HSP27 (pS82) or phospho-eNOS (pS1177) (magenta). (I) Microvessel 























Mouse retinal explants were stimulated and stained as described in (G) using 
phospho-specific antibodies to p38, HSP27 and eNOS. ns non-significant, ***p < 


























Figure 3. VEGF-A and Bradykinin induced AMPK phosphorylation.  
(A-C) Primary brain microvascular ECs were stimulated with VEGF-A from the apical 
or basal side for 5 min triggering apically (group I), basally specific (group III) or 
mixed (group II) responses (see text or ref Hudson et al., 2014 for more details) (A). 
Cells were lysed and phosphorylation of indicated molecules assessed by 
phosphoantibody array analysis (B-C). (D-G) brain microvascular ECs (D, F) or ex-
vivo rat retinae (E, G) were stimulated with 50 ng/ml VEGF-A (D, E) or 10 μM BK (F, 
G) for the indicated length of time and AMPKα phosphorylation (pT172) analysed. 
Representative results and quantification of AMPKα activation from three 
independent experiments are shown as normalised means ± SD. *p < 0.05, **p < 


























Figure 4. AMPK mediated VEGF-A/Bradykinin-induced permeability.  
(A-F) Rat ex-vivo retinae were preincubated with or without Compound-C (CC, 10 
μM) for 15 min. 10 ng/ml VEGF-A (A, B) or 10 μM BK (C, D) were then applied to the 
top of the retina and changes in permeability recorded. Alternatively (E, F), retinae 
were immunostained using IB4 (green) and anti-phospho-p38, -HSP27 or -eNOS 
antibodies (magenta) as detailed in Figure 2. (G-N) AMPKα1 specific siRNA or 
scrambled control was injected into the vitreous of mouse eyes. After 72 h retinae 
were isolated, lysed and subjected to immunoblotting using AMPKα1- and tubulin-























independent immunoblots as shown in (G). Knock-down retinae were also prepared 
for ex vivo permeability measurements and stimulated using VEGF-A (50 ng/ml) (J, 
K) or BK (10 μM) (L, M). Alternatively, retinae were fixed and immunostained using 
IB4 (green) and anti-AMPKα1 (I), phospho-p38, -HSP27 or -eNOS antibodies 
(magenta) (N). Note that neither PIF induced any permeability in the AMPKα1 
knocked-down retina. Representative results and quantifications (normalized mean ± 
SD) from data points from independent experiments are shown. **p < 0.01, ***p < 


























Figure 5. Stimulation of AMPK induced permeability in the ex vivo retina.  
(A-D) Ex vivo preparations were stimulated with the two different AMPK activators 
PF739 (10 μM) and MK8722 (10 μM). Both agonists induced strong and immediate 
permeability in the ex vivo retinal microvessels. Mean (± SD) permeability changes 
recorded from three retinae are shown in (B, D). (E) Ex vivo retinae were stimulated 
as in (A-D) and after 2 min fixed using 4% PFA and then immunostained using IB4 
(green) and or anti-phospho-p38, -HSP27 or -eNOS (magenta) as detailed in Figure 

























Figure 6. VEGF-A- and Bradykinin-induced permeability requires Ca2+, CaMKK, 
p38 and eNOS.  
(A-E) Ex vivo retinae were preincubated with 20 µM BAPTA (Ca2+ chelator) (A, E as 
indicated), 10 µM STO-609 (STO, CaMKK inhibitor) (B, E as indicated), 10 µM L-
NAME (NOS inhibitor) (C, E as indicated), or 10 µM SB202190 (SB, p38 inhibitor) 























retina (abluminal side) and changes in microvessel permeability were recorded as 
described in Figure 2. Alternatively (E), retinae were fixed after 2 min using 4 % PFA 
and then immunostained with IB4 (green) and for phosphorylation of p38, HSP27 
and eNOS (magenta). (F-J) As in panels (A-E), except that ex vivo retinae were 
stimulated with BK (10 μM). Representative results and quantifications (independent 
data points and means ± SD) are shown. *p < 0.05, **p < 0.01, ***p < 0.001. Scale 


























Figure 7. VEGF-A and Bradykinin induced VE-Cadherin phosphorylation. 
(A) Ex vivo retinae were preincubated with SU1498 (10 µM), or BAPTA (20 µM) or 
STO (10 µM) and treated with VEGF-A and Bradykinin for 2 min. Retinae were then 
fixed with 4% PFA and immunostained for phospho-AMPKα (magenta) and with IB4 
(green). (B) Ex vivo retinae were preincubated with compound C (10 µM), or L-























and immunostained for phosphorylated VE-cad (using anti-pY685-VEC) (magenta) 
and with IB4 (green). (C) AMPKα1 specific siRNA or scrambled control were injected 
into the vitreous of mouse eyes. After 72 h retinae were treated with VEGF-A and 
Bradykinin for 2 min and immunostained for phosphorylated VE-cad (using anti-
pY685-VEC) (magenta) and with IB4 (green). (D) Proposed signalling networks in 
the ex-vivo retinal microvasculature downstream of VEGF-A and Bradykinin. Scale 






















































































































Figure S1. Properties of the ex vivo retina model. (A-B) Selected frames, pseudocoloured in (B), of 
time-resolved recordings of a Sulforhodamine-B-filled rat capillary before and after the addition of 50 ng/ml 
VEGF-A, illustrating the rapid loss of fluorophore from the lumen of the vessel. The red box 
exemplifies a typical r.o.i used for intensity measurement. Scale bars, 10 µm. (C-G) CLDN5 siRNA was 
injected into mouse eyes. 72 h later CLDN5 levels were analysed by immunoblots of retinal lysates (C-D) 
or by wholemount immunochemical staining (E). Scale bar, 100 µm. Alternatively, permeability of 4 kDa 
Rhodamine was measured in ex vivo retinae from CLDN5 siRNA or control injected eyes (F), with 
quantifications (independent data points, means ± SD) shown in (G). (H, I) AMPKα1 specific siRNA or 
scrambled control was injected into the vitreous of mouse eyes. After 72 h retinae were isolated, lysed and 
subjected to immunoblotting as indicated using anti-pan-AMPKα-specific and -tubulin antibodies (H). 





















































Figure S2. Additional AMPK stimulation experiments in the ex-vivo retina. (A-D) Ex vivo 
preparations were stimulated with the AMPK activators A769662 (10 μM, A-B) and AICAR (10 μM, C-
D). Both agonists induced strong and immediate permeability in the ex vivo retinal microvessels. Mean (± 
SD) permeability changes recorded from three retinae are shown in (B, D). (E) Ex vivo retinae were 
stimulated as in (A-D) and after 2 min fixed using 4% PFA and then immunostained using IB4 (green) 
and or anti-phospho-p38, -HSP27 or -eNOS antibodies (magenta) as detailed in Figure 2. *p < 0.05. 































































































































































Control DEANO ODQ ODQ + DEANO
Figure S 3. Sensitivity of AMPK-dependent permeability signalling to inhibitors of soluble 
guanylyl cyclase and PAK. (A) Ex vivo preparations were pre-incubated with or without ODQ (10 μM) 
for 15 min and then stimulated with the NO donor DEANO (10 μM). After 5 min, the ex-vivo retinae 
were fixed using 4% PFA and immunostained using IB4 (green) and for phospho-VE-Cad 
(magenta). (B, C) Ex vivo retinae were preincubated with or without FRAX597 (10 μM) for 15 min and 
stimulated with the VEGF-A (10 ng/ml, B) or the AMPK activator PF739 (10 μM, C). Shown are mean (± 
SD) permeability changes recorded from three retinae (ns, non signficant). (D, E) Ex vivo retinae were 
stimulated with or without FRAX597 (10 μM) for 15 min or 1h, stimulated with VEGF-A (10 ng/ml, D) or 
PF739 (10 μM, E) for 5 min, fixed using 4% PFA and then immunostained using IB4 (green) and for 
phospho-p38 (magenta). Scale bars, 10 μm. Note that FRAX597 was used at ca. 1000 x of the reported 
IC50 for PAK1-3. Other,  similar ATP-binding site inhibitors used in this study, e.g. SB202190, were highly 
effective in the ex vivo retina at significantly lower relative inhibitory concentrations (200 x IC50), 











































































Figure S4. Samples of original western blots. To optimize our samples and save animals, we cut the 
membrane based on the molecular weight and we obtained stripes that we incubated with different 
antibodies. AMPK (60 kDa) and Tubulin (55 kDa) have a similar molecular weight. We tried to blot them 
together but the bands were too close (A) and to obtain nicer figures we opted for GAPDH (144 kDa) (D, E). 
Samples of P-AMPK (60 kDa) are shown in (B, C). Lanes 1 to 5 for all membranes: Control – 0.5 min – 2 
min – 5 min – 10 min VEGF-A (10ng/ml).














































Anti-Claudin 5 (4C3C2) Mouse mAb, ThermoFisher Scientific, Product# 35-2500. Citation: 
https://www.thermofisher.com/antibody/product/Claudin-5-Antibody-clone-4C3C2-
Monoclonal/35-2500 
Anti-α-Tubulin Mouse mAb, Merck, Product# T9026. Citation: 
https://www.sigmaaldrich.com/catalog/product/sigma/t9026?lang=en&region=GB 
Anti-Phospho-Y658-VEC, produced and purified by New England Peptide. Citation: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514492/ 
J. Cell Sci.: doi:10.1242/jcs.253179: Supplementary information
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